Home > Haematology > ASH 2021 > Multiple Myeloma > MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

Presented By
Prof. Philippe Moreau, University Hospital of Nantes, France

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 1/2, MajesTEC-1
Teclistamab was safe and efficacious in patients with relapsed/refractory multiple myeloma (MM). The results of the phase 1/2 MajesTEC-1 trial showed durable and deepening responses in a triple-class exposed population. A phase 3 study, MajesTEC-3, is currently ongoing to further assess teclistamab in patients with MM [1]. Teclistamab is an off-the-shelf, T cell-directing antibody binding to CD3 on T cells and BCMA on plasma cells. The open-label, multicentre, phase 1/2 MajesTEC-1 trial (NCT04557098) included patients with relapsed/refractory MM who received at least 3 prior lines of therapy and were triple-class exposed (n=165). The patients were treated with 1.5 mg/kg teclistamab, subcutaneously administered once weekly. The primary endpoint was the overall response rate. Prof. Philippe Moreau (University Hospital of Nantes, France) presented the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on